We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Mammoth Biosciences Presents AACC 2021 Disruptive Technology Award Finalist CRISPR-Based Detection Platform

By LabMedica International staff writers
Posted on 29 Sep 2021

Illustration

Mammoth Biosciences (San Francisco, CA, USA) presented its revolutionary CRISPR-based detection platform that is enabling limitless testing possibilities and was also one of the AACC 2021 Disruptive Technology award finalists.

Mammoth has catalyzed a new approach to molecular diagnostics, called DETECTR. Based on CRISPR, this programmable platform acts as a search engine for biology and is capable of finding and identifying any nucleic acid sequence in the genome. Using proprietary technology licensed exclusively from the University of California, Berkeley and developed internally, Mammoth is working on multiple form factors and test targets from infectious diseases to cancer. For example, DETECTR was configured in less than two weeks to detect SARS-CoV-2, demonstrating the platform’s ability to be quickly tailored to identify any DNA or RNA target. The resulting product, DETECTR BOOST, is a reagent kit that when combined with standard laboratory automation provides labs with unparalleled high throughput molecular testing.

Mammoth was also one of the AACC 2021 Disruptive Technology award finalists. AACC's Disruptive Technology Award Competition recognizes innovative testing and disruptive technology solutions that improve patient care through diagnostic performance or access to high quality testing. It provides an opportunity for early to mid-stage start-ups in the medical device, diagnostic, or digital health/health IT spaces to showcase their technology and present to a large audience and a panel of judges.

Related Links:
Mammoth Biosciences

Visit expo >

New

Gold Member

POC Helicobacter Pylori Test Kit

Hepy Urease Test

Online QC Software
Acusera 24•7

New

Platelet Function Analyzer

PL-12

All-in-One Molecular System

AIO M160

ADLM

Latest AACC 2021 News

Channels

Clinical Chemistry

view channel

Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Blood Biomarker Reveals Hidden Disability Progression in Multiple Sclerosis

Multiple sclerosis (MS) remains difficult to monitor because neurological decline can continue even after relapses stop. This progression independent of relapse activity is often subtle and may escape... Read more

Image Credit: iStock

Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis

Alzheimer’s disease is often first suspected in primary care, yet definitive evaluation frequently depends on specialized imaging or cerebrospinal fluid testing. This creates a persistent gap between disease... Read more

Machine Learning Model Shows Promise for Improving Metanephrine Testing Accuracy

Pheochromocytomas and paragangliomas are rare tumors that form in or near the adrenal glands and cause overproduction of stress hormones. Plasma-free metanephrines are the recommended first-line test,... Read more

Molecular Diagnostics

view channel

New PCR Assays Expand Cyclospora Testing for Outbreak Surveillance

Cyclospora cayetanensis, a food- and waterborne intestinal parasite, can cause prolonged diarrhea, fatigue, and abdominal cramping, placing added strain on urgent care and emergency departments during outbreaks.... Read more

Single Liquid Biopsy Predicts Early Immunotherapy Benefit in Advanced Lung Cancer

Assessing early benefit from immunotherapy in advanced non-small cell lung cancer can be challenging because radiographic responses may take months to become clear. Early scans can also be difficult to... Read more

Machine Learning Tool Improves Prediction of Liver Cancer Recurrence

Recurrent hepatocellular carcinoma (HCC) after surgery remains a major cause of poor outcomes and contributes to liver cancer’s rank as the world’s third leading cause of cancer death. The burden is particularly... Read more

AI-Powered Liquid Biopsy Detects Liver Cancer Across Diverse Populations

Liver cancer remains a leading cause of cancer mortality worldwide, with incidence rising alongside the growing burden of metabolic liver disease. Early detection can substantially improve outcomes, yet... Read more

Hematology

view channel

Ultra-Portable Device Enables Finger-Prick Blood Testing at Home

Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read more

Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam

Complete blood count (CBC) results underpin pediatric evaluation for anemia, infection, inflammation, and platelet disorders. Yet laboratories in Vietnam have largely relied on reference intervals derived... Read more

Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma

Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read more

Image: Despite treatment advances, most multiple myeloma patients relapse and identifying high-risk cases at diagnosis remains challenging (Image Credit: Adobe Stock)

New Marker Helps Detect Aggressive Multiple Myeloma Earlier

Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read more

Immunology

view channel

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more

Image: A new study shows that an ultrasensitive blood test can detect immune signaling patterns associated with Sjögren’s disease more than a decade before diagnosis (Image Credit: 123RF)

Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis

Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more

New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients

Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read more

Microbiology

view channel

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Proteomic Workflow Maps Microbial and Host Responses in Intestinal Inflammation

The intestinal microbiome influences digestion, metabolism, and immunity, yet its complexity makes functional measurements difficult to obtain. DNA surveys can indicate which organisms and potential pathways... Read more

Metagenomic Sequencing Enables Faster Diagnosis of Respiratory Infections in Cystic Fibrosis

Serious lung infections remain a major cause of morbidity among people with cystic fibrosis, a life-threatening genetic disorder characterized by persistent airway colonization and frequent antimicrobial exposure.... Read more

Image: Lassa fever remains a major public health threat in West Africa, causing 100,000–300,000 infections annually and high fatality rates, making faster site-based diagnosis critical for care and outbreak control (Image Credit: Shutterstock)

Portable Molecular Platform to Advance Point-of-Care Testing for Lassa Fever

Lassa fever remains a persistent public health threat in West Africa, causing an estimated 100,000–300,000 infections annually and high case fatality rates among hospitalized patients. Clinical management... Read more

Pathology

view channel

AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer

Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more

AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy

Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more

PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more

AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer

Breast cancer diagnostic workflows increasingly depend on accurate quantification of immunohistochemical biomarkers to guide therapy selection, yet manual scoring can be variable and time-consuming.... Read more

Technology

view channel

Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results

Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more

Training Device Improves Accuracy of Pooled Molecular Diagnostics

High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more

New CE-Certified Software Advances Whole-Genome Cancer Testing

European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more

National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care

Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read more

Industry

view channel

Image: Professor David Brettle, Chief Scientific Officer at Leeds Teaching Hospitals NHS Trust with a pathology slide showing the TANGO technology (Photo courtesy of Leeds Teaching Hospitals NHS Trust)

Standardized Staining Technology Advances Digital Pathology Workflows

Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more

Global Testing Service Advances Leukemia MRD Monitoring

KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more

Ultrasensitive MRD Assay Gains Medicare Coverage for Immunotherapy and Breast Cancer Monitoring

Patients with late-stage solid tumors and breast cancer often require repeated monitoring to assess recurrence risk and treatment response. Minimal residual disease (MRD) testing is intended to detect... Read more

Genprex and Roche Collaborate on AI-Driven NSCLC Biomarker Testing

Patient stratification is central to advancing targeted oncology, yet clinical laboratories still face hurdles establishing robust, decision-ready biomarkers for non-small cell lung cancer.... Read more